• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布托啡诺对阿片类药物滥用者的激动剂效应及急性身体依赖性:与吗啡的比较。

Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine.

作者信息

Greenwald M K, Stitzer M L

机构信息

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 48207, USA.

出版信息

Drug Alcohol Depend. 1998 Dec 1;53(1):17-30. doi: 10.1016/s0376-8716(98)00104-5.

DOI:10.1016/s0376-8716(98)00104-5
PMID:10933337
Abstract

This study compared the direct effects and acute physical dependence of butorphanol and morphine, opioids with differing actions at mu versus kappa receptors. Six non-dependent heroin-using volunteers were exposed to six conditions in a within-subject, Latin square design using double-blind procedures. In each session, agonist effects of single i.m. injections of butorphanol (3 and 6 mg/70 kg), morphine (15 and 30 mg/70 kg), lorazepam (4 mg/70 kg) or saline were evaluated. Butorphanol and morphine produced effects of comparable magnitude on miosis and reports of 'any drug effect'. Volunteers reported dysphoria, confusion and sedation after butorphanol, subjective effects that overlapped with those of lorazepam, whereas morphine produced euphoria and stimulation. Acute physical dependence (i.e. precipitated withdrawal responses to naloxone 10 mg/70 kg i.m. administered 6 h after each treatment) significantly increased after 30 mg/70 kg morphine but not after butorphanol treatments. These differences in naloxone sensitivity are likely due to differences in opioid receptor (mu versus kappa) activity, affinity and efficacy of these compounds. Pharmacological ramifications of these results are discussed.

摘要

本研究比较了布托啡诺和吗啡的直接作用及急性身体依赖性,这两种阿片类药物对μ受体和κ受体的作用不同。采用双盲程序,在一项受试者自身的拉丁方设计中,让6名无依赖性的海洛因使用者志愿者暴露于六种条件下。在每次实验中,评估单次肌肉注射布托啡诺(3毫克/70千克和6毫克/70千克)、吗啡(15毫克/70千克和30毫克/70千克)、劳拉西泮(4毫克/70千克)或生理盐水的激动剂效应。布托啡诺和吗啡对瞳孔缩小及“任何药物效应”的报告产生的效应程度相当。志愿者在使用布托啡诺后报告有烦躁不安、意识模糊和镇静作用,这些主观效应与劳拉西泮的效应重叠,而吗啡则产生欣快感和兴奋作用。在接受30毫克/70千克吗啡治疗后,急性身体依赖性(即每种治疗后6小时肌肉注射10毫克/70千克纳洛酮引发的戒断反应)显著增加,而布托啡诺治疗后则未增加。纳洛酮敏感性的这些差异可能是由于这些化合物在阿片受体(μ受体与κ受体)活性、亲和力和效能方面存在差异。讨论了这些结果的药理学意义。

相似文献

1
Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine.布托啡诺对阿片类药物滥用者的激动剂效应及急性身体依赖性:与吗啡的比较。
Drug Alcohol Depend. 1998 Dec 1;53(1):17-30. doi: 10.1016/s0376-8716(98)00104-5.
2
Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.孤束旁核中κ-阿片受体介导的局灶性依赖和戒断反应
Pharmacol Biochem Behav. 2002 Dec;74(1):241-52. doi: 10.1016/s0091-3057(02)00993-0.
3
Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain.从对布托啡诺的依赖中戒断会独特地增加大鼠大脑中κ(1)-阿片受体的结合。
Brain Res Bull. 2002 Jun;58(2):149-60. doi: 10.1016/s0361-9230(02)00760-8.
4
Changes in the brain kappa-opioid receptor levels of rats in withdrawal from physical dependence upon butorphanol.丁丙诺啡身体依赖戒断大鼠脑κ-阿片受体水平的变化。
Neuroscience. 2003;121(4):1063-74. doi: 10.1016/s0306-4522(03)00299-9.
5
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.通过纳曲酮差异阻断评估布托啡诺在人体中的μ和κ阿片样物质作用。
Psychopharmacology (Berl). 2008 Jan;196(1):143-55. doi: 10.1007/s00213-007-0948-z. Epub 2007 Oct 2.
6
Relative involvement of spinal opioid receptors in physical dependence on intrathecal butorphanol and morphine.脊髓阿片受体在鞘内注射布托啡诺和吗啡所致身体依赖性中的相对参与情况。
Pharmacol Biochem Behav. 1998 Aug;60(4):899-907. doi: 10.1016/s0091-3057(98)00074-4.
7
Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8.蛋白激酶可能参与阿片类物质身体依赖性:使用蛋白激酶抑制剂H-7和H-8的研究。
Eur J Pharmacol. 1995 Sep 15;284(1-2):101-7. doi: 10.1016/0014-2999(95)00370-z.
8
Mu- and delta-opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence.μ-阿片受体拮抗剂和δ-阿片受体拮抗剂在布托啡诺和吗啡依赖中引发相似的戒断现象。
Neurochem Res. 1996 Jan;21(1):63-71. doi: 10.1007/BF02527673.
9
Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.纳洛酮能在预先短暂给予GM1神经节苷脂的未接触过药物的小鼠或慢性吗啡依赖小鼠中迅速诱发内源性κ阿片受体介导的痛觉过敏。
Brain Res. 2007 Sep 5;1167:31-41. doi: 10.1016/j.brainres.2007.06.058. Epub 2007 Jul 14.
10
Naloxone-precipitated changes in biogenic amines and their metabolites in various brain regions of butorphanol-dependent rats.纳洛酮引起的丁丙诺啡依赖大鼠不同脑区生物胺及其代谢产物的变化。
Pharmacol Biochem Behav. 1996 Jun;54(2):461-8. doi: 10.1016/0091-3057(95)02213-9.

引用本文的文献

1
Etorphine induces pathophysiology in immobilized white rhinoceros through sympathomimesis that is attenuated by butorphanol.埃托啡通过拟交感神经作用在固定的白犀牛中诱发病理生理学,而布托啡诺可减弱这种作用。
Conserv Physiol. 2025 Apr 4;13(1):coaf009. doi: 10.1093/conphys/coaf009. eCollection 2025.
2
Strategies for Developing Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.开发具有更少副作用的治疗疼痛的阿片受体激动剂的策略。
J Pharmacol Exp Ther. 2020 Nov;375(2):332-348. doi: 10.1124/jpet.120.000134. Epub 2020 Sep 10.
3
Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
纳呋拉啡作为一种阿片类药物节约辅助药物的临床前测试,该药物通过靶向μ阿片受体的激动剂吗啡增强镇痛作用。
J Pharmacol Exp Ther. 2019 Nov;371(2):487-499. doi: 10.1124/jpet.118.255661. Epub 2019 Sep 6.
4
and Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.PPL-101和PPL-103简介:具有低滥用潜力的混合阿片类部分激动剂镇痛药。
Front Psychiatry. 2017 Apr 12;8:52. doi: 10.3389/fpsyt.2017.00052. eCollection 2017.
5
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.通过纳曲酮差异阻断评估布托啡诺在人体中的μ和κ阿片样物质作用。
Psychopharmacology (Berl). 2008 Jan;196(1):143-55. doi: 10.1007/s00213-007-0948-z. Epub 2007 Oct 2.